Secukinumab (Anti‐IL‐17A Therapeutic Antibody) Improves Clinical Outcome for a Mixed Endotype CRS
Mihkel Plaas, Agnieska Brazovskaja, Kai Kisand, Liina Tserel, Pärt Peterson · 2024
Read Secukinumab (Anti‐IL‐17A Therapeutic Antibody) Improves Clinical Outcome for a Mixed Endotype CRS by Mihkel Plaas, Agnieska Brazovskaja, Kai Kisand, Liina Tserel, Pärt Peterson (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11626084.txt.
Description
Mihkel Plaas and four co-authors report two sinus patients whose disease answered to a different immune drug after the standard biologic failed, in this 2024 paper. Chronic rhinosinusitis with nasal polyps is often driven by type II inflammation, and an antibody blocking that pathway helps many patients. These two patients did not respond, and their blood signals suggested a mixed pattern, part type II and part type III.
The team switched them to secukinumab, an antibody that blocks interleukin-17, the signature messenger of type III inflammation. On the new drug, their polyp scores and symptom scores improved beyond what the earlier antibody had achieved. Two patients prove nothing alone. Yet the cases argue that sinus disease comes in immune flavors. Matching the drug to the flavor, even a mixed one, may rescue patients written off as biologic failures.
Catalog record
| CREATOR | Mihkel Plaas, Agnieska Brazovskaja, Kai Kisand, Liina Tserel, Pärt Peterson |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 11 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |